Samyang Biopharm (KRX: 0120G0)
Who is buying Samyang Biopharm?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net bought ₩1.9bn ($1M) of Samyang Biopharm, the 97th largest foreign net purchase among 832 KOSPI stocks. Institutions net sold ₩0.6bn ($0M) and retail investors net sold ₩1.0bn ($1M) over the same window. Foreigners were net buyers on 11 of the 20 sessions.
Foreign investors hold 3.37% of Samyang Biopharm's listed shares (KRX ownership data as of Oct 13, 2026), up from 2.72% twenty sessions earlier.
The stock closed at ₩43,250 on Oct 13, 2026: -12.45% over 20 sessions, -17.62% year-to-date. The 52-week range is ₩23,250 – ₩150,900.
At ₩43,250 the stock trades at 143.69× trailing earnings (KRX, last completed fiscal year); no analyst consensus is available for a forward P/E.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩43,250 | +₩0.0bn | ₩-0.1bn | ₩-0.1bn |
| 2026-10-12 | ₩44,550 | ₩-0.9bn | +₩0.0bn | +₩0.7bn |
| 2026-10-08 | ₩48,150 | ₩-0.2bn | ₩-0.3bn | +₩0.6bn |
| 2026-10-07 | ₩49,900 | ₩-0.2bn | +₩0.0bn | +₩0.4bn |
| 2026-10-06 | ₩50,600 | +₩0.8bn | ₩-0.1bn | ₩-0.3bn |
| 2026-10-02 | ₩48,400 | ₩-0.2bn | ₩-0.0bn | +₩0.4bn |
| 2026-10-01 | ₩49,200 | +₩1.0bn | +₩0.1bn | ₩-1.1bn |
| 2026-09-30 | ₩46,550 | +₩0.4bn | +₩0.0bn | ₩-0.5bn |
| 2026-09-29 | ₩45,400 | ₩-0.7bn | ₩-0.0bn | +₩0.4bn |
| 2026-09-28 | ₩47,350 | +₩0.4bn | ₩-0.0bn | ₩-0.4bn |
| 2026-09-23 | ₩46,500 | +₩0.1bn | ₩-0.4bn | +₩0.3bn |
| 2026-09-22 | ₩46,900 | +₩0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-09-21 | ₩47,050 | ₩-0.0bn | +₩0.1bn | ₩-0.0bn |
| 2026-09-18 | ₩47,850 | ₩-0.9bn | ₩-0.1bn | +₩1.0bn |
| 2026-09-17 | ₩49,550 | +₩1.0bn | +₩0.2bn | ₩-1.1bn |
| 2026-09-16 | ₩46,600 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-09-15 | ₩48,050 | +₩0.8bn | ₩-0.0bn | ₩-0.8bn |
| 2026-09-14 | ₩47,700 | +₩0.2bn | ₩-0.0bn | ₩-0.1bn |
| 2026-09-11 | ₩49,000 | ₩-0.0bn | +₩0.2bn | ₩-0.2bn |
| 2026-09-10 | ₩49,800 | +₩0.5bn | ₩-0.0bn | ₩-0.5bn |
| 2026-09-09 | ₩49,400 | +₩0.3bn | ₩-0.0bn | ₩-0.3bn |
| 2026-09-08 | ₩49,000 | +₩0.0bn | ₩-0.1bn | ₩-0.1bn |
| 2026-09-07 | ₩50,200 | +₩0.3bn | +₩0.0bn | ₩-0.1bn |
| 2026-09-04 | ₩49,850 | +₩0.9bn | +₩0.0bn | ₩-1.0bn |
| 2026-09-03 | ₩48,150 | ₩-0.4bn | +₩0.0bn | ₩-0.0bn |
| 2026-09-02 | ₩52,100 | ₩-0.8bn | +₩0.2bn | +₩1.1bn |
| 2026-09-01 | ₩53,500 | ₩-0.9bn | +₩0.1bn | +₩0.6bn |
| 2026-08-31 | ₩55,300 | ₩-1.5bn | ₩-0.0bn | +₩1.6bn |
| 2026-08-28 | ₩54,800 | +₩0.1bn | ₩-0.1bn | ₩-0.1bn |
| 2026-08-27 | ₩54,800 | ₩-0.9bn | ₩-0.1bn | +₩1.1bn |
| 2026-08-26 | ₩58,200 | ₩-0.5bn | +₩0.1bn | +₩0.7bn |
| 2026-08-25 | ₩54,700 | ₩-3.0bn | +₩0.0bn | +₩2.6bn |
| 2026-08-24 | ₩62,100 | ₩-1.4bn | +₩0.1bn | +₩1.6bn |
| 2026-08-21 | ₩58,800 | ₩-5.4bn | ₩-1.2bn | +₩8.8bn |
| 2026-08-20 | ₩56,200 | ₩-1.1bn | +₩0.6bn | +₩0.4bn |
| 2026-08-19 | ₩43,300 | ₩-0.0bn | +₩0.0bn | +₩0.0bn |
| 2026-08-18 | ₩45,450 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-08-14 | ₩47,950 | ₩-0.2bn | ₩-0.1bn | +₩0.2bn |
| 2026-08-13 | ₩48,600 | ₩-0.1bn | +₩0.3bn | ₩-0.1bn |
| 2026-08-12 | ₩46,850 | ₩-0.4bn | +₩0.2bn | +₩0.3bn |
| 2026-08-11 | ₩47,650 | +₩0.1bn | +₩0.2bn | +₩0.1bn |
| 2026-08-10 | ₩46,550 | +₩0.0bn | +₩0.0bn | +₩0.1bn |
| 2026-08-07 | ₩43,950 | ₩-0.0bn | +₩0.0bn | +₩0.0bn |
| 2026-08-06 | ₩44,650 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-05 | ₩44,250 | ₩0.0bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-04 | ₩44,500 | +₩0.2bn | ₩-0.0bn | ₩-0.2bn |
| 2026-08-03 | ₩39,650 | +₩0.4bn | +₩0.0bn | ₩-0.4bn |
| 2026-07-31 | ₩38,500 | +₩0.5bn | ₩-0.0bn | ₩-0.5bn |
| 2026-07-30 | ₩33,900 | +₩1.4bn | ₩-0.0bn | ₩-1.6bn |
| 2026-07-29 | ₩35,500 | +₩0.2bn | ₩-0.1bn | ₩-0.2bn |
| 2026-07-28 | ₩38,000 | ₩-0.1bn | ₩-0.0bn | +₩0.0bn |
| 2026-07-27 | ₩41,700 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-07-24 | ₩41,450 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-07-23 | ₩42,300 | +₩1.3bn | ₩-0.5bn | ₩-0.8bn |
| 2026-07-22 | ₩39,750 | ₩-0.2bn | ₩-0.2bn | +₩0.4bn |
| 2026-07-21 | ₩40,050 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-07-20 | ₩41,000 | ₩-0.0bn | ₩-0.1bn | +₩0.1bn |
| 2026-07-16 | ₩42,700 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-07-15 | ₩44,900 | ₩-0.0bn | +₩0.0bn | ₩-0.1bn |
| 2026-07-14 | ₩43,300 | +₩0.1bn | ₩0.0bn | ₩-0.2bn |
| 2026-07-13 | ₩43,400 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩0.0bn | +$0M | ₩-0.1bn | ₩-0.1bn |
| 5 days | ₩-0.5bn | $-0M | ₩-0.5bn | +₩1.4bn |
| 20 days | +₩1.9bn | +$1M | ₩-0.6bn | ₩-1.0bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Samyang Biopharm stock?
Over the last 5 sessions foreign investors net sold ₩0.5bn ($0M) of Samyang Biopharm; over 60 sessions they net sold ₩9.6bn ($7M); since Jan 1, 2026 they net sold ₩17.8bn ($13M). Over 20 sessions the stock is the 97th largest foreign net purchase among 832 KOSPI stocks.
How much of Samyang Biopharm do foreign investors own?
Foreign investors own 3.37% of Samyang Biopharm's shares as of Oct 13, 2026. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩0.6bn ($0M) and retail investors net sold ₩1.0bn ($1M) of Samyang Biopharm. Foreign buying is being met mainly by retail selling.
Is Samyang Biopharm listed on KOSPI or KOSDAQ?
Samyang Biopharm (삼양바이오팜) trades on KOSPI under KRX code 0120G0 in the Biotech & Pharma group, with a market capitalization of ₩0T ($0.2B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2025 | ₩29bn ($21M) | – | ₩3bn ($2M) | ₩2bn ($2M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.